Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,capitalSurplus,totalLiab,totalStockholderEquity,otherCurrentLiab,totalAssets,otherCurrentAssets,retainedEarnings,treasuryStock,otherAssets,cash,totalCurrentLiabilities,otherStockholderEquity,propertyPlantEquipment,totalCurrentAssets,accountsPayable,netReceivables,changeToLiabilities,totalCashflowsFromInvestingActivities,totalCashFromFinancingActivities,changeToOperatingActivities,issuanceOfStock,changeInCash,totalCashFromOperatingActivities,depreciation,changeToAccountReceivables,changeToNetincome,capitalExpenditures,effectOfExchangeRate,netBorrowings,WC,language,region,quoteType,triggerable,quoteSourceName,currency,esgPopulated,tradeable,exchangeDataDelayedBy,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,earningsTimestamp,earningsTimestampStart,earningsTimestampEnd,epsTrailingTwelveMonths,epsForward,regularMarketChangePercent,regularMarketDayRange,regularMarketPreviousClose,bid,ask,bidSize,askSize,messageBoardId,fullExchangeName,longName,financialCurrency,averageDailyVolume3Month,averageDailyVolume10Day,bookValue,fiftyDayAverage,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverage,twoHundredDayAverageChange,twoHundredDayAverageChangePercent,marketCap,forwardPE,priceToBook,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,gmtOffSetMilliseconds,priceHint,exchange,marketState,market,shortName,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,"Shares Short (May 27, 2021) 4","Short Ratio (May 27, 2021) 4","Short % of Float (May 27, 2021) 4","Short % of Shares Outstanding (May 27, 2021) 4","Shares Short (prior month Apr 29, 2021) 4",Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,fullTimeEmployees,compensationRisk,auditRisk,longBusinessSummary,city,phone,state,shareHolderRightsRisk,compensationAsOfEpochDate,governanceEpochDate,boardRisk,country,website,maxAge,overallRisk,address1,fax,industry
t0,CYCN,48433000.0,40420900,8092000,,-13399000,,-13399000,5365000,-8030000,-13395000,-13395000,,-4000,,,,0,62000,13457000,8092000,-4000,,-13399000,-13399000,225288000.0,51534000.0,48433000.0,375000.0,99967000.0,104000.0,-176828000.0,-27000.0,6518000.0,41429000.0,13467000.0,-27000.0,49003000.0,44446000.0,1095000.0,,-340000.0,1462000.0,27000.0,-3401000.0,27000.0,-12966000.0,-14455000.0,258000.0,127000.0,2300000.0,,,,30979000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,USD,False,False,0,1.3100002,0.62980783,2.08 - 8.96,-5.5699997,-0.62165177,2.08,8.96,1614259800,1614259800,1614259800,-2.217,-1.0,-0.87719214,3.38 - 3.39,3.42,3.33,3.4,13,10,finmb_561493203,NasdaqGS,"Cyclerion Therapeutics, Inc.",USD,1276151,239966,1.419,3.2408333,0.14916682,0.046027306,3.3708696,0.019130468,0.0056752325,137026848,-3.39,2.3890064,15,America/New_York,EDT,-14400000,4,NMS,REGULAR,us_market,"Cyclerion Therapeutics, Inc.",3.39,1630503183,-0.029999971,3.165,3.39,3.38,7658,1.84,,,8.96,2.08,3.2408,3.3709,1.28M,239.97k,40.42M,,23.72M,17.42%,68.32%,1.55M,1.75,5.81%,4.55%,1.02M,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",0.00%,"-5,150.82%",-36.06%,-109.21%,1.34M,0.04,-93.90%,2.3M,-67.3M,-70.97M,-2.2170,,41.43M,1.21,44.96M,92.83,3.30,1.42,-57.77M,-30.37M,Value,02142,Healthcare,34,8,7,"Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of medicines for serious central nervous system (CNS) diseases. Its product candidates include CY6463, a CNS-penetrant, soluble guanylate cyclase (sGC) stimulator that is in Phase II trials for the treatment of mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS) and Alzheimer's disease with vascular pathology (ADv); Olinciguat, an orally administered vascular soluble guanylate cyclase stimulator that is in Phase II studies for the treatment of sickle cell disease (SCD); Praliciguat, an orally administered systemic sGC stimulator that is in Phase II trials for the treatment of diabetic nephropathy and heart failure with preserved ejection fraction. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.",Cambridge,857 327 8778,MA,2,1609372800,1622505600,5,United States,http://www.cyclerion.com,86400,4,301 Binney Street,617 890 6595,Biotechnology
t-1,CYCN,59493000.0,40420900,11192000,,-19228000,,-19228000,3765000,133000,-14824000,-14824000,,-4000,,,,0,133000,14957000,0,-4404000,,-19228000,-19228000,222949000.0,55885000.0,59493000.0,176000.0,115378000.0,1563000.0,-163429000.0,-27000.0,6610000.0,54395000.0,16952000.0,-27000.0,50267000.0,58501000.0,1149000.0,127000.0,-416000.0,1436000.0,159000.0,1700000.0,159000.0,-12446000.0,-14041000.0,470000.0,272000.0,3161000.0,-35000.0,,,41549000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,USD,False,False,0,1.3100002,0.62980783,2.08 - 8.96,-5.5699997,-0.62165177,2.08,8.96,1614259800,1614259800,1614259800,-2.217,-1.0,-0.87719214,3.38 - 3.39,3.42,3.33,3.4,13,10,finmb_561493203,NasdaqGS,"Cyclerion Therapeutics, Inc.",USD,1276151,239966,1.419,3.2408333,0.14916682,0.046027306,3.3708696,0.019130468,0.0056752325,137026848,-3.39,2.3890064,15,America/New_York,EDT,-14400000,4,NMS,REGULAR,us_market,"Cyclerion Therapeutics, Inc.",3.39,1630503183,-0.029999971,3.165,3.39,3.38,7658,1.84,,,8.96,2.08,3.2408,3.3709,1.28M,239.97k,40.42M,,23.72M,17.42%,68.32%,1.55M,1.75,5.81%,4.55%,1.02M,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",0.00%,"-5,150.82%",-36.06%,-109.21%,1.34M,0.04,-93.90%,2.3M,-67.3M,-70.97M,-2.2170,,41.43M,1.21,44.96M,92.83,3.30,1.42,-57.77M,-30.37M,Value,02142,Healthcare,34,8,7,"Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of medicines for serious central nervous system (CNS) diseases. Its product candidates include CY6463, a CNS-penetrant, soluble guanylate cyclase (sGC) stimulator that is in Phase II trials for the treatment of mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS) and Alzheimer's disease with vascular pathology (ADv); Olinciguat, an orally administered vascular soluble guanylate cyclase stimulator that is in Phase II studies for the treatment of sickle cell disease (SCD); Praliciguat, an orally administered systemic sGC stimulator that is in Phase II trials for the treatment of diabetic nephropathy and heart failure with preserved ejection fraction. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.",Cambridge,857 327 8778,MA,2,1609372800,1622505600,5,United States,http://www.cyclerion.com,86400,4,301 Binney Street,617 890 6595,Biotechnology
t-2,CYCN,75354000.0,40420900,13703000,,-18812000,,-18812000,8033000,400000,-21336000,-21336000,,-4000,,,,0,400000,21736000,0,2524000,,-18812000,-18812000,219582000.0,56048000.0,75354000.0,343000.0,131402000.0,1666000.0,-144201000.0,-27000.0,6702000.0,66840000.0,16262000.0,-27000.0,54576000.0,70124000.0,1360000.0,400000.0,-728000.0,3000.0,24267000.0,2177000.0,24267000.0,9225000.0,-15048000.0,588000.0,351000.0,1376000.0,-9000.0,3000.0,,53862000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,USD,False,False,0,1.3100002,0.62980783,2.08 - 8.96,-5.5699997,-0.62165177,2.08,8.96,1614259800,1614259800,1614259800,-2.217,-1.0,-0.87719214,3.38 - 3.39,3.42,3.33,3.4,13,10,finmb_561493203,NasdaqGS,"Cyclerion Therapeutics, Inc.",USD,1276151,239966,1.419,3.2408333,0.14916682,0.046027306,3.3708696,0.019130468,0.0056752325,137026848,-3.39,2.3890064,15,America/New_York,EDT,-14400000,4,NMS,REGULAR,us_market,"Cyclerion Therapeutics, Inc.",3.39,1630503183,-0.029999971,3.165,3.39,3.38,7658,1.84,,,8.96,2.08,3.2408,3.3709,1.28M,239.97k,40.42M,,23.72M,17.42%,68.32%,1.55M,1.75,5.81%,4.55%,1.02M,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",0.00%,"-5,150.82%",-36.06%,-109.21%,1.34M,0.04,-93.90%,2.3M,-67.3M,-70.97M,-2.2170,,41.43M,1.21,44.96M,92.83,3.30,1.42,-57.77M,-30.37M,Value,02142,Healthcare,34,8,7,"Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of medicines for serious central nervous system (CNS) diseases. Its product candidates include CY6463, a CNS-penetrant, soluble guanylate cyclase (sGC) stimulator that is in Phase II trials for the treatment of mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS) and Alzheimer's disease with vascular pathology (ADv); Olinciguat, an orally administered vascular soluble guanylate cyclase stimulator that is in Phase II studies for the treatment of sickle cell disease (SCD); Praliciguat, an orally administered systemic sGC stimulator that is in Phase II trials for the treatment of diabetic nephropathy and heart failure with preserved ejection fraction. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.",Cambridge,857 327 8778,MA,2,1609372800,1622505600,5,United States,http://www.cyclerion.com,86400,4,301 Binney Street,617 890 6595,Biotechnology
t-3,CYCN,66101000.0,40420900,13794000,,-19534000,,-19534000,6627000,749000,-19672000,-19672000,,-4000,,,,0,749000,20421000,0,138000,,-19534000,-19534000,191520000.0,61937000.0,66101000.0,579000.0,128038000.0,89000.0,-125389000.0,-30000.0,6383000.0,56462000.0,15645000.0,-30000.0,62093000.0,59562000.0,2213000.0,751000.0,1096000.0,-65000.0,3663000.0,-859000.0,154000.0,-10635000.0,-14221000.0,613000.0,275000.0,4188000.0,-75000.0,-12000.0,3509000.0,43917000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,USD,False,False,0,1.3100002,0.62980783,2.08 - 8.96,-5.5699997,-0.62165177,2.08,8.96,1614259800,1614259800,1614259800,-2.217,-1.0,-0.87719214,3.38 - 3.39,3.42,3.33,3.4,13,10,finmb_561493203,NasdaqGS,"Cyclerion Therapeutics, Inc.",USD,1276151,239966,1.419,3.2408333,0.14916682,0.046027306,3.3708696,0.019130468,0.0056752325,137026848,-3.39,2.3890064,15,America/New_York,EDT,-14400000,4,NMS,REGULAR,us_market,"Cyclerion Therapeutics, Inc.",3.39,1630503183,-0.029999971,3.165,3.39,3.38,7658,1.84,,,8.96,2.08,3.2408,3.3709,1.28M,239.97k,40.42M,,23.72M,17.42%,68.32%,1.55M,1.75,5.81%,4.55%,1.02M,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",0.00%,"-5,150.82%",-36.06%,-109.21%,1.34M,0.04,-93.90%,2.3M,-67.3M,-70.97M,-2.2170,,41.43M,1.21,44.96M,92.83,3.30,1.42,-57.77M,-30.37M,Value,02142,Healthcare,34,8,7,"Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of medicines for serious central nervous system (CNS) diseases. Its product candidates include CY6463, a CNS-penetrant, soluble guanylate cyclase (sGC) stimulator that is in Phase II trials for the treatment of mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS) and Alzheimer's disease with vascular pathology (ADv); Olinciguat, an orally administered vascular soluble guanylate cyclase stimulator that is in Phase II studies for the treatment of sickle cell disease (SCD); Praliciguat, an orally administered systemic sGC stimulator that is in Phase II trials for the treatment of diabetic nephropathy and heart failure with preserved ejection fraction. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.",Cambridge,857 327 8778,MA,2,1609372800,1622505600,5,United States,http://www.cyclerion.com,86400,4,301 Binney Street,617 890 6595,Biotechnology
